• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Amphetamine Extended Release Oral Suspension for ADHD

Amphetamine Extended Release Oral Suspension for ADHD

September 1, 2018
Rehan Aziz, MD.
From The Carlat Child Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Rehan Aziz, MD. Dr. Aziz has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Review of: Childress AC et al, J Child Adolesc Psychopharmacol 2017;28(5):306–313

In 2015, the FDA approved Dyanavel XR (amphetamine extended release oral suspension), which was the first long-acting liquid version of amphetamine on the market. To provide some context, Quillivant XR, a long-action liquid methylphenidate formulation, was approved in 2012 and appears to be fairly popular for kids who can’t or won’t swallow pills. Seeing a market opportunity, Tris Pharmaceuticals developed Dyanavel XR and funded a placebo-controlled trial that was successful enough to gain FDA approval. Recently, this study was published, and some readers might be curious to look at the quality of the data.

The study took place at 5 investigational sites in the US. A total of 108 boys and girls with ADHD (ages 6–12) were initially enrolled in a 5-week open-label phase in which all patients were given Dyanavel XR, starting at 2.5–5 mg and titrated up to a target dose of 10–20 mg/day. Nine of the children dropped out of this first phase, and 99 continued on to the placebo-controlled phase of the study. Participants were randomly assigned to either Dyanavel XR (51 patients, mean dose 17.3 mg) or placebo (48 patients). After 1 week on the medication, the children’s ADHD symptoms were evaluated with a teacher-rated instrument called the SKAMP (for the Swanson, Kotkin, Agler, M-Flynn, and Pelham Rating Scale).

The primary outcome variable was improvement in SKAMP scores from pre-dose to post-dose of medication. Dyanavel XR was more effective than placebo beginning 1 hour after the dose and continuing for 13 hours. The effect size was a very robust 1.8, in line with effect sizes reported in similar trials of other long-acting stimulants. In terms of side effects, patients on Dyanavel XR reported decreased appetite (26%), insomnia (13%), and affect lability (9%), with no substantial differences in blood pressure or pulse between the treatment and control group.

CCPR’s take
Not too surprisingly, Dyanavel XR is an effective stimulant treatment for ADHD. This study was not huge but was well-designed, and the results were judged to be robust enough to merit FDA approval. It’s another arrow in our ever-expanding quiver of stimulant options, and this liquid formulation will likely be just as popular as Quillivant XR. Being a brand-name option, its cost is high. For families that want cheaper liquid stimulants, go with either generic ProCentra (short-acting dextroamphetamine) or Methylin oral solution (short-acting methylphenidate).
Child Psychiatry
KEYWORDS adhd research-update
Rehan Aziz, MD.

Mood Stabilizers for Bipolar Disorder in Older Adults: Special Considerations

More from this author
www.thecarlatreport.com
Issue Date: September 1, 2018
SUBSCRIBE NOW
Table Of Contents
CME Post-Test - Depression in Children and Adolescents, CCPR, September/October 2018
Amphetamine Extended Release Oral Suspension for ADHD
Resilience Networks in Adolescent Females at Risk for Major Depression
Note From the Editor-in-Chief
Antidepressant-Induced Suicidality: What It Is and What You Should Do
Current Use of Antidepressant Medication in Children
Depression in Transition to Adulthood: A Case Study
Bullying and Suicidality: Some Practical Tips
CBT vs Pharmacotherapy for Childhood Anxiety
DOWNLOAD NOW
Featured Book
  • CMFB2e_Cover.png

    Child Medication Fact Book for Psychiatric Practice, Second Edition (2023)

    All the important facts covering child and adolescent psychopharmacology.
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • canstockphoto29377983.jpg
    Child Psychiatry

    Anxiolytics in Children and Adolescents

    Learn about the pros and cons of the main categories of medications that clinicians typically use to treat anxiety in children and adolescents.

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.